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ADULT UROLOGY
A DOSE-RESPONSE STUDY OF THE EFFECT OF FLUTAMIDE
ON BENIGN PROSTATIC HYPERPLASIA:
RESULTS OF A MULTICENTER STUDY
PERINCHERY NARAYAN JOHN TRACHTENBERG, HERBERT LEPOR, EM.J. DEBRUYNE, 
ASHUTOSH TEWARI, NELSON STONE, SAKTl DAS, J.E JIMENEZ-CRUZ, ROBERT SHEARER,
IRA KLIMBERG, PAUL E SCHELLHAMMER, ANTHONY J. COSTELLO,
a n d  MEMBERS OF THE MULTI CENTER TRIAL*
A B S T R A C T
O b j e c t i v e s .  T h e  o b j e c t i v e  o f  t h i s  s t u d y  w a s  t o  e v a l u a t e  e ff icacy ,  s a f e t y ,  a n d  d o s e - r e s p o n s e  p r o f i l e s  o f  f o u r  d o s ­
in g  s c h e m e s  o f  f l u t a m i d e  o v e r  2 4  w e e k s .
M e t h o d s .  P a t i e n t s  w e r e  r a n d o m i z e d  t o  r e c e iv e  o n e  o f  t h e  fo l lo w in g  f iv e  t r e a t m e n t  r e g i m e n s  f o r  a  p e r i o d  o f  
2 4  w e e k s :  p l a c e b o  c a p s u l e ,  f l u t a m i d e  c a p s u l e s  1 2 5  m g  tw ic e  d a i ly ,  2 5 0  m g  o n c e  d a i ly ,  2 5 0  m g  t w i c e  d a i ly ,  
a n d  2 5 0  m g  t h r e e  t i m e s  d a i ly .  P a t i e n t s  w e r e  t h e n  e v a l u a t e d  a t  b a s e l i n e  (0  w e e k s )  a n d  a t  4 ,  6 , 1 2 ,  1 8 ,  a n d  
2 4  w e e k s  a f t e r  t h e  s t a r t  o f  t r e a t m e n t ,  a n d  8  w e e k s  a f t e r  t h e  e n d  o f  t r e a t m e n t  ( 3 2  w e e k s ) .  E v a l u a t i o n  o f  effi­
c a c y  w a s  p e r f o r m e d  b y  n o t i n g  c h a n g e s  in u r i n e  flow r a t e ,  r e s i d u a l  u r i n e  v o l u m e ,  s y m p t o m  s c o r e ,  p r o s t a t e  v o l ­
u m e ,  a n d  p r o s t a t e - s p e c i f i c  a n t i g e n  level.  A  t o t a l  o f  3 7 2  p a t i e n t s  w e r e  e n r o l l e d  i n t o  t h e  s t u d y  a t  3 2  c e n t e r s  
( 1 4  c e n t e r s  in t h e  U n i t e d  S t a t e s  a n d  1 8  i n t e r n a t i o n a l  c e n t e r s ) .
R e s u l t s .  B a s e l i n e  p e a k  u r i n a r y  flow r a t e  a n d  p e r c e n t  c h a n g e  f r o m  b a s e l i n e  in m a x i m u m  f lo w  r a t e  s h o w e d  a  
d o s e - r e l a t e d  i n c r e a s e  a t  4  a n d  6  w e e k s ;  t h i s  i n c r e a s e  w a s  s ig n i f i c a n t  in t h e  2 5 0  m g  t h r e e  t i m e s  d a i l y  g r o u p .  
A t  l a t e r  t i m e  p o i n t s ,  n o  s ig n i f i c a n t  d i f f e r e n c e s  b e t w e e n  t h e  f l u t a m i d e  a n d  p l a c e b o  g r o u p s  w e r e  o b s e r v e d ,  
l a rg e ly  b e c a u s e  o f  t h e  d e c r e a s i n g  n u m b e r  o f  e v a l u a b l e  p a t i e n t s .  A t  4  a n d  6  w e e k s ,  2 5 %  o f  p a t i e n t s  in t h e  
2 5 0  m g  t h r e e  t i m e s  d a i ly  g r o u p  h a d  m o r e  t h a n  3  cc /s  i n c r e a s e  in u r o f lo w  c o m p a r e d  t o  a b o u t  1 0 %  o f  p l a c e b o  
p a t i e n t s  (P  < 0 . 0 5 ) .  All f l u t a m i d e - t r e a t e d  g r o u p s  h a d  a  s i g n i f i c a n t  d e c r e a s e  in p r o s t a t e  v o l u m e  f r o m  b a s e l i n e  
t o  t h e  l a s t  t r e a t m e n t  v is i t  c o m p a r e d  t o  p l a c e b o  a n d  t h i s  r e d u c t i o n  w a s  d o s e  r e l a t e d  (in c o m p a r i s o n  t o  p l a c e b o :  
P  < 0 . 0 5  f o r  1 2 5  m g  tw ic e  d a i ly  a n d  P  < 0 . 0 0 1  f o r  all o t h e r  t r e a t m e n t  a r m s ) .  M e d i a n  d e c r e a s e  f o r  t h e  f lu­
t a m i d e - t r e a t e d  g r o u p s  r a n g e d  f r o m  6 % to  2 3 %  a t  1 2  w e e k s  a n d  f r o m  1 4 %  t o  2 9 %  a t  2 4  w e e k s .  All t r e a t ­
m e n t  g r o u p s  s h o w e d  a  s u b s e q u e n t  i n c r e a s e  in p r o s t a t e  v o l u m e  a f t e r  t r e a t m e n t  w a s  s t o p p e d .  F u r t h e r m o r e ,  
t h e r e  w a s  a  s ig n i f i c a n t  r e d u c t i o n  in r e s id u a l  u r i n e  v o l u m e  a t  2 4  w e e k s  o n l y  in t h e  2 5 0  m g  t h r e e  t i m e s  d a i ly  
g r o u p .  It i n c r e a s e d  fo l lo w in g  c e s s a t i o n  o f  t h e r a p y .  U r in a r y  s y m p t o m s  a t  6 , 1 2 ,  1 8 ,  a n d  2 4  w e e k s  d i d  n o t  s h o w  
a n y  s ig n i f i c a n t  d i f f e r e n c e  b e t w e e n  p l a c e b o  a n d  a n y  f l u t a m i d e  d o s e  g r o u p .  T h e  m o s t  c o m m o n  a d v e r s e  e v e n t s  
w e r e  n ip p le  a n d  b r e a s t  t e n d e r n e s s  ( 4 2 %  t o  5 2 % ) ,  d i a r r h e a  ( 2 9 %  t o  3 4 % ) ,  a n d  g y n e c o m a s t i a  ( 1 4 %  t o  1 9 % ) .  
E a c h  o f  t h e s e  a d v e r s e  e v e n t s  h a d  a  s ig n i f ic a n t ly  h i g h e r  i n c i d e n c e  in all f l u t a m i d e  d o s e  g r o u p s  c o m p a r e d  w i th  
p l a c e b o ,  b u t  n o n e  a p p e a r e d  t o  o c c u r  in a  d o s e - r e l a t e d  f a s h i o n .  S i x t e e n  p e r c e n t  o f  p a t i e n t s  in t h e  p l a c e b o  
g r o u p  a n d  2 5 %  t o  3 9 %  o f  p a t i e n t s  in f l u t a m id e  g r o u p s  w e r e  d i s c o n t i n u e d  d u e  t o  d i a r r h e a  ( 1 2 %  t o  1 7 % )  o r  
n i p p l e  a n d  b r e a s t  t e n d e r n e s s  (4 %  t o  8 %). A  t o t a l  o f  1 %  t o  3 %  o f  p a t i e n t s  in v a r i o u s  t r e a t m e n t  a r m s  d i s c o n ­
t i n u e d  d u e  t o  d e r a n g e d  l iver  e n z y m e s  (1 % fo r  p l a c e b o ) ;  a n d  1 %  t o  4 %  d u e  t o  i m p o t e n c e  (1 %  f o r  p l a c e b o ) .  
C o n c l u s i o n s .  F l u t a m i d e  r e d u c e d  t h e  p r o s t a t e  v o l u m e  in a  d o s e - r e l a t e d  f a s h i o n  a n d  r e s u l t e d  in a n  i n c r e a s e  in 
p e a k  f low  r a t e  a t  4  w e e k s  ( 3 %  fo r  2 5 0  m g  t h r e e  t i m e s  d a i ly ,  P  v a l u e  <  0 . 0 5 ) ,  b u t  t h e  e a r l y  p o s i t i v e  e f f e c t s  
d id  n o t  m a i n t a i n  s t a t i s t i c a l  s ig n i f ic a n c e  d u e  t o  a n  i n c r e a s i n g  n u m b e r  o f  d r o p o u t s  d u e  t o  a d v e r s e  e v e n t s .  Ef­
f e c t  o n  p o s t v o i d  r e s i d u a l  v o l u m e  w a s  o b s e r v e d  o n ly  a t  t h e  h i g h e s t  d o s e  a n d  a t  2 4  w e e k s  ( m e d i a n  r e d u c t i o n ,
2 3  m L , P  < 0 . 0 5 ) .  D e s p i t e  v o l u m e  r e d u c t i o n  a n d  e a r l y  i m p r o v e m e n t  in p e a k  f lo w  r a t e ,  t h e r e  w e r e  n o  s ig n i f ­
i c a n t  d i f f e r e n c e s  in u r i n a r y  s y m p t o m s  a m o n g  t h e  p l a c e b o  a n d  f l u t a m i d e  g r o u p s .  H i g h e r  i n c i d e n c e s  o f  d i a r ­
r h e a ,  b r e a s t  t e n d e r n e s s ,  a n d  g y n e c o m a s t i a ,  h o w e v e r ,  w e r e  t h e  m a i n  l i m i t i n g  f a c t o r s  in t h i s  s t u d y  a n d  u n t i l  
t h e s e  p r o b l e m s  a r e  o v e r c o m e ,  t h e  ro le  o f  f l u t a m i d e  in t h e  m a n a g e m e n t  o f  b e n i g n  p r o s t a t i c  h y p e r p l a s i a  r e ­
m a i n s  i n v e s t i g a t i o n a l .  UROLOGY* 47: 4 9 7 - 5 0 4 ,  1 9 9 6 .
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Benign prostatic hyperplasia (BPH), a disease of aging men, affects half of all men over 50 years 
of age.1 Transurethral resection of the prostate is 
the most common method used to treat BPH and 
approximately 30,000 prostatectomies are per­
formed annually in the United States. Financial 
implications to treat BPH are enormous and up to 
$2 billion are spent every year.2 Recent reports, 
however, have suggested that up to 20% of men 
undergoing transurethral resection of the prostate 
are not relieved of their symptoms23 and up to 
18% morbidity is associated with the procedure.2 
These factors have resulted in an intense search 
for medical management of BPH.
Prostate tissue is androgen dependent and both 
dihydro testosterone (DHT) and testosterone play 
a key role in the development of BPH. Various 
medical approaches have been used to deprive the 
prostate of its androgenic stimulation. Flutamide 
(Eulexin) is a potent nonsteroidal antiandrogen 
that inhibits the binding of testosterone and DHT 
to androgen receptors, and it has been used rou­
tinely to treat carcinoma of the prostate (CaP). As 
a logical extension to its role in treatment of CaP, 
pilot studies have been conducted to evaluate the 
efficacy and safety of flutamide in treating BPH. 
In a double-blind, placebo-controlled study in­
volving 30 patients, a significant reduction in 
prostate volume was observed in patients receiv­
ing 300 mg/day of flutamide.3 However, there were 
no differences in uroflow parameters or postvoid 
residual urine (PVR). In another double-blind 
study using higher dosage (750 mg/day) of flu­
tamide, significant reduction in prostate volume, 
residual urine, and improvement in peak flow rate 
and symptoms were observed,4,5 However, the op­
timum safe dose of flutamide to treat BPH was 
still not established. The objective of this study 
was to evaluate efficacy, safety, and dose-response 
profiles of four dosing schemes of flutamide over
24 weeks.
MATERIAL AND METHODS
This  d o u b le -b l in d ,  p laceb o -con tro l led ,  rrmlticentr ic  s tudy  
was c o n d u c te d  over  2.5 years (July  1990 to  D ecem ber 1992), 
in co m p l ian ce  w i th  the code  o f  federal regu la t ions  in  the 
U n ited  S ta tes ,  a f te r  o b ta in in g  a w r i t te n  in fo rm e d  co n sen t  
p r io r  to e n ro l lm e n t .  T he  in c lu s ion  cri ter ia  o f  the s tu d y  i n ­
c luded  a clinical d iag n os is  of BPH; age b e tw e e n  40 a n d  90 
years; g o o d  physica l  a n d  m e n ta l  health ;  p a t ien t  agreeable 
a n d  m o t iv a t e d  fo r  p a r t i c ip a t in g  fo r  th e  d u r a t io n  o f  the 
s tudy ; p e a k  u r in a ry  f low  ra te  (PFR ) less th a n  15 cc/s (vo ided  
vo lum e  m o re  th a n  150 cc); sy m p to m s  o f  u r in a ry  o b s t ru c ­
tion  (as m e n t io n e d  la ter  in  th is  sec t ion ) ;  en la rged  p ro s ta te  
on digita l rectal e x a m in a t io n ;  a n d  a n o rm a l  renal a n d  h e ­
patic func t ion .  T h e  ex c lu s io n  cri teria  in c lu d e d  co n co m itan t  
use  of m ed ica t io n s  p o ten t ia l ly  capable  o f  in terfer ing  w ith  
p ros ta te  sy m p to m s ;  ev idence  of n e u ro g e n ic  b ladder,  b la d ­
der n e c k  c o n t r a c tu re ,  u r e th r a l  s t r ic tu re ,  p ro s ta t i t is ,  CaP, 
and  u n re so lv e d  u r in a ry  trac t  in fec t ion  (U TI);  p r io r  su rgery  
for BPH; u r in a ry  r e t e n t io n  r e q u i r in g  ca the te r iza t ion ;  c u r ­
ren t  cardiac p ro b lem s  (m yocardia l  in fa rc t ion  in  the  last 3 
m o n th s )  o r  renal failure (se rum  crea tin ine  m ore  th an  2.5 
mg/dL); p rev io u s  ex p o su re  to f lu tam ide  o r  o th e r  a n t i a n ­
drogens; se ru m  calc ium  m ore  than  11 mg/dL; s e ru m  g lu ­
tamic oxaloacetic t ransam inase  (SGOT) or  se ru m  g lu tam ic  
pyruvic  t ransam inase  (SGPT) m ore  than  2 t im es the  n o r ­
mal u p p e r  limit; any  significant medical or psychia tr ic  ill­
ness tha t  w o u ld  e i ther  p reven t  the pa tien t  from com ply ing  
w ith  the p ro to co l  a n d  giving in fo rm ed  co n sen t  or w o u ld  
likely deteriorate  du r ing  the study. Patien ts  w ere  r a n d o m ­
ized to receive one  of the  following five t re a tm en t  reg im en s  
for a period of 24 weeks; Placebo capsule, f lu tam ide cap ­
sules 125 m g twice daily, 250 m g once  daily, 250 m g  twice 
daily, and  250  m g  th ree  t im es daily. P a t ien ts  w ere  th e n  
evaluated at baseline  (0 weeks) a n d  at 4, 6 , 12, 18, a n d  24 
weeks after the  s tart  of t rea tm en t,  a n d  8 w eeks after the end 
of t rea tm en t  (32 w eeks) .  At baseline, de ta i led  m edica l  and  
gen itourinary  h istory , inc lud ing  h is to ry  of acute  u r in a ry  re ­
ten t io n  a n d  o th e r  u ro lo g ic  co m p la in ts ,  w ere  n o te d .  T he  
u r in a ry  s y m p to m s  in c lu d e d  f re q u e n c y  (d ay  a n d  n ig h t ) ,  
size and  force of s t ream , hesitancy, n eed  to s t ra in  o r  p u sh  
to s ta r t  flow, u rgency ,  te rm ina l  d ribb ling ,  p a in fu l  or b u r n ­
ing sensa t ion ,  in te r ru p t io n  in  u r in a ry  s t ream , a n d  se n sa ­
tion o f  in co m p le te  em pty ing , At the time of  the s ta r t  o f  the 
s tu d y ,  A m er ican  U ro lo g ica l  A sso c ia t io n  sympLom sco re  
was n o t  ava i lab le ,  h e n c e ,  th ese  s y m p to m s  w e re  g ra d e d  
from  0  (n o n e  o r  never)  to 4  (very severe  o r  a lw ays) a c ­
co rd ing  to a p red ica ted  scale. Patien ts  w ere  also asked  to 
g rad e  each  type  o f  u r in a r y  s y m p to m  a c c o r d in g  to h o w  
troub lesom e  it was from 0 (no t t ro u b le so m e)  to 6 (very 
troub lesom e) ,  an d  to identify  the m o s t  t ro u b le so m e  s y m p ­
tom, Additionally ,  pa t ien ts  were to g rade  the ir  overa ll  u r i ­
nary  p ro b le m s  f rom  0 ( n o n e )  to 6 (very  sev e re ) .  O th e r  
tests  p e r fo rm e d  a t  base l ine  in c lu d e d  u r in a ry  flow ra tes ,  
transrecta l  so n o g ra p h y  to estimate p ros ta te  size and  PVR 
u r in e ,  s e ru m  for p ros ta te -sp ec if ic  a n t ig e n  (PSA), te s to s ­
terone, lu te in iz ing  h o rm o n e ,  estradio l l ip op ro te in  profile, 
com ple te  b lo o d  c o u n t ,  a n d  sem en  analysis, in c lu d in g  sp e rm  
co u n t ,  m o rp h o lo g y ,  a n d  motili ty . T he  safety o f  m ed ic a t io n  
was evaluated  by adverse  events  an d  s ignificant changes  in 
labora to ry  values. Criteria  for rem oval from the s tu d y  in ­
c luded  d eve lo p m en t  o f  ser ious  UTI; need  for m a jo r  su rge ry  
or any  o th e r  re a so n  in te r fe r ing  w ith  p a r t ic ip a t in g  in the 
s tudy; allergic reac t ion  to the drug; u n c o n t ro l le d  d ia rrhea ;  
desire to w i th d ra w  from  the s tu d y  by the  p a t ie n t  hasecl on  
subjective toxicity  o r  un re la ted  personal reasons; need  for 
c o n c o m ita n t  m ed ica t io n s  (an t ich o l in e rg ic s ,  cho l ine rg ics ,  
o r  h o rm o n e s )  that  m ay  in terfere  w ith  the p ros ta te  c o n d i ­
tion; d e te r io ra t ing  ren a l  func t ion  seco n d a ry  to obs truc t ive  
uropathy ;  a n d  p o o r  p a t ien t  com pliance .  E valua tion  of effi­
cacy was p e r fo rm ed  by n o t in g  changes  in u r in e  flow rate ,  
res idua l  u r in e  v o lu m e ,  sy m p to m  score, p ro s ta te  vo lum e ,  
and PSA,
S t a t i s t i c a l  A n a l y s i s
Efficacy param eters  were analyzed by  an analysis o f  vari­
ance m o d e l  u s in g  ra n k s  Tather than values. C o m p a r iso n s  
am ong trea tm ent groups were made for baseline values and  
percent change from  baseline for all efficacy param eters  ex ­
cept urinary  sym ptom s, for w hich  the change from baseline 
instead of percen t  change was compared. Pairwise c o m p a r ­
isons for each trea tm ent combination were done  using least 
squares m eans and  the  pooled s tandard  deviation from the 
analysis of variance. Any pa t ien t  w ith  m issing  baseline  or 
missing response w as excluded from the analysis. All adverse 
events o r  concurren t  illness with reports of m ore  than  5 p a ­
tients in  any of the trea tm ent groups were analyzed using  
Fisher’s exact test. Pairwise com parisons were perform ed us­
ing Fisher’s exact test.
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TABLE I. Age and race of intent-to-treat population by treatment group
Treatment Group
Baseline
Patient Features
Placebo 
{n = 74)
125 mg BID 
(n = 75)
250  mg OD 
(n « 69)
250  mg BID 
(n = 74)
250  mg TID
(n = 75)
Age (years)
65Mean 66 66 67 66
Median 65 66 67 68 66
Range 4 5 -7 8 42-85 4 7 -8 0 4 8 -8 8 4 3 -8 0
Race (no. patients)
White 70 68 65 70 69
Black 3 2 2 2 2
Other 1 5 2 2 4
K j:'y: BID = twice daily; OD  = on«: t/iii/y ; TID  = i l irc i’ finu's cim'fy.
TABLE II. Final disposition of all enrolled patients
Treatment Group (%)
Results
Placebo 
(n = 74)
125 mg BID
(n = 75)
250 mg OD 
(n = 70)
250 mg BID 
(n = 77)
250  mgTI 
(n = 76)
Completed study 52 (70) 46 (61) 43 (61) 36 (47) 40 (53)
Adverse experience 7 (9) 17 (23) 19* (27) 25 (32) 25 (33)
Treatment failure 3(4) 0 (0) 1 (1) 1 (1) 2(3)
Did not return/lost to follow-up 5 (7) 4(5) 2 (3) 5 (6 ) 3(4)
Concurrent illness 5(7) 2 (3) 2 (3) 4 (5 ) 1 (1)
Noncompliance 2(3) 4(5] 1 (1) 4 (5 ) 3 (4)
Did not meet entrance criteria 0(0) 1 (1) 0 (0) 0 (0 ) 1 (1)
Administrative 0(0) 1 (1) 1 (1) 2 (3) 1 (1)
Death 0(0) 0(0) 1 (1)* 0 (0 ) 0(0)
Kfiv: BJD = hvirc daily ; OD = oncc daily; 77D = l Jim: i/cii/y.
*Onr patient was initially (at 4 weeks) removed f r o m  the s tudy due to elevated S C O T  and S G P T  and later he died due tu cerebrovascular accident at 24  w e d «  (SOOT mu/ 
SOPT Jiwf /)tTonie nomuil by this time). Death not deemed drug related by the investigator.
'T h is  patient was severely depressed, had fa m i ly  problems, cind confimtfiliy com/jliiined o f  chronic bach pain. He shot his wife and  com m itted  suicide. Death was  nof 
deemed  d rug  rWafcfl by the investigator.
RESULTS
A total of 372 patients were enrolled into the 
study at 32 centers (14 centers in the United States 
and 18 international centers). Five patients failed 
to return after baseline visit for a variety of rea­
sons and were therefore excluded from all analy­
ses. The remaining 367 patients constitute the in- 
tent to treat population. The baseline patient 
characteristics are shown in Table 1.
Of the 367 patients, 217 (59%) completed the 
study (Table II). Of the 367 patients, 93 (25%)
each time point. A dose-related increase ap­
peared to occur at 4 and 6 weeks; this increase 
was significant in the 250 mg three times daily 
group. At later time points, no significant dif­
ferences between the flutamide and placebo 
groups were observed, largely because of the de­
creasing number of evaluable patients. All treat­
ment groups showed a decrease in PFR follow­
ing cessation of therapy. Table IV shows the 
number and percentage of patients with an in­
crease in PFRs of at least 3 m U s  from baseline.
discontinued due to adverse experience. Of the A dose-related effect is again apparent, espe-
367 patients in the intent-to-treat population, 57 dally at 4 and 6 weeks, when about 25% of pa-
(16%) were excluded from the efficacy population tients in the 250 mg three times daily group had
for various reasons, including insufficient med- such an increase compared with about 10% of
ication, noncompliance, insufficient efficacy data. 
(See Material and Methods for criteria of removal.)
placebo patients (P <0.05).
All flutamide-treated groups had a significant
Due to the large number of patients excluded from decrease in prostate volume from baseline to the 
the efficacy population, the analysis of efficacy last treatment visit compared with placebo, and
presented in this report is based on the intent-to- 
treat population. However, for completeness, all 
efficacy analyses except those for urinary symp-
this reduction was dose related (Table V; in com­
parison to placebo: P <0.05 for 125 mg twice daily 
and P <0.001 for all other treatment arms). Me-
toms were analyzed for the 310 patients in the ef- dian decrease for the flutamide-treated groups
ficacy population and results were not different. ranged from 6% to 23% at 12 weeks and from
Table 111 shows the baseline PFR and percent 14% to 29% at 24 weeks. All treatment groups
change from baseline in maximum flow rate at showed a subsequent increase in prostate volume
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TABLE III. Percent change from baseline in maximum urinary flow rate 
by treatment group by week
Time 
Since 
Baseline
Baseline (mL\s)
After 4 weeks 
After 6 weeks 
After 12 weeks 
After 18 weeks 
After 24 weeks
8 weeks post-treatment
Key: BID = twice daily, OD = once daily;  TID = three  times daily.
* P <0.05 compared ta placebo.
Placebo
1T Ô  
-6  (68 ) 
- 7  (64) 
5 (64) 
- 3  (56) 
-1  (52) 
- 8  (54)
125 mg BID
T L 3
- 6  (7 3)
-2  (72)
5 (68)
0 (55)
- 4  (48)
11 (48)
Treatment Group 
250 mg OD
10.4 
- 4  (62)
1 (62)*
4(58)
4(49)
- 3  (45)
-1 0  (45)
2 50 mg BID
7 0 / 2
- 4  (68)
- 2  (64)
0 (53)
- 2  (43)
21 (37)
- 5  (39)
250 mg TID
1 1.2 
3 (72)*
9 (64)* 
-1 (55)
13 (42)
1 1 (38)
3 (43)
TABLE IV. Number and percentage of patients with an increase in maximum urinary flow rate of 
at least 3 mL/s from baseline by treatment group by week
Treatment Group (%)
Baseline Placebo 125 mg BID 250 mg OD 250 mg BID 250 mg TID
After 4 weeks 7/68 (10) 15/73 (21) 10/62 (16) 13/68 (19) 17/72 (24)*
After 6 weeks 6/64 (9) 13/72 (18) 11/62 (18) 15/64 (23)* 16/64 (25)*
After 12 weeks 12/64 (19) 14/68 (21) 15/58 (26) 10/53 (19) 14/55 (26)
After 18 weeks 11/56 (20) 1 1/55 (20) 8/49 (1 6) 8/43 (19) 13/42 (31)
After 24 weeks 11/52 (21) 8/48 (17) 9/45 (20) 17/37 (46)* 1 0/38 (26)
8 weeks post-treatment 9/54 (17) 6/48 (13) 6/45 (13) 4/39 (10) 1 3/43 (30)
Key; BID = twice daily; OD  = once daily; TID  = three times daily. 
*P <0.05 compared to placebo.
TABLE V. Prostate volume by treatment group at baseline and at last treatment visit
_________________________ Treatment Group_________________________
Placebo 125 mg BID 2 5 0 m g O D  250 mg BID 250 mg TID 
Median Values (mL) (n » 66) (n -  69) (n = 62) (n = 57) (n = 58)
Prostate volume at baseline 39.8 4073 47.1 * 38.0 4376
Prostate volume at last treatment visit 37.5 36.1 38.6 31.3* 31.3*
% Change in prostate volume -2 %  -1 3 % * -19% * -1 7 % * - 2 1 % *
K ey: BID  = twice daily ; OD = once daily; TfD = three times daily.
*P <0.05 compared to placebo.
after treatment was stopped (only 4% to 18% re­
duction from baseline in the flutamide group and 
1% in the placebo group).
As shown in Table VI, there was a significant re­
duction in residual urine volume at 24 weeks only 
in the 250 mg three times daily group. It increased 
following cessation of therapy.
Table VII shows urinary symptoms at 6, 12, 18, 
and 24 weeks of treatment, and there was no sig­
nificant difference between placebo and any flu­
tamide dose group at any of the time points.
All flutamide groups had significant dose-re­
lated reduction in PSA during treatment. Median 
PSA for the 250 mg three times daily group de­
creased from 3.0 ng/mL at baseline to 1.0 ng/mL 
at the end of treatment. At 24 weeks, flutamide- 
treated patients had a median decrease of 40% to
60% in PSA. It rose back lo baseline following 
stoppage of treatment.
A d v e r s e  E v e n t s  a n d  C o n c o m i t a n t  I l l n e s s
The most common adverse events in various treat­
ment arms were nipple and breast tenderness (42% 
to 52%), diarrhea (29% to 34%), and gynecomastia 
(14% to 19%) (Table VIII). Each of these adverse 
events had a significantly higher incidence in all 
flutamide dose groups compared with placebo, but 
none appeared to occur in a dose-related fashion. 
Severe diarrhea was reported in 40 flutamide-treated 
patients ranging from 8% in the 125 mg twice daily 
group to 17% in the 250 mg three times daily group. 
There were no occurrences of life-threatening diar­
rhea. Severe nipple or breast pain occurred in 11 pa­
tients in the flutamide arms (equally distributed in
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TABLE VL Summary of residual volume 
for 24 weeks
No. of
Analysis Based on 
Intent to Treat
Patients Population Median (mL)
Baseline
Placebo 53 67.0
125 BID 46 46.0
250 OD 45 55.0
250 BID 34 50.0
250 TID 34 90.0
Response 24 Weeks
Placebo 53 60.0
125 BID 46 43.0
250 OD 45 60.0
250 BID 37 47.6
250 TID 37 40.0
Change 24 Weeks
Placebo 53 -4 .0
125 BID 46 -2 .0
250 OD 45 -1 0 .0 *
250 BID 37 10.0*
250 TID 37 23.0*
Key: BID -  iwicc daily; OD = once daily; TIL> -  three times  dnity.
*P <0.05 compared to placcbo.
each dose) but in none of the patients receiving 
placebo. Similarly severe gynecomastia occurred in
5 flutamide patients (3 in the 125 mg twice daily 
and 2 in the 250 mg twice daily groups), but none 
occurred in placebo patients. Two patients died dur­
ing the study: 1 shot his wife and committed sui­
cide, and the other, who was diabetic type I I ,  died 
of a cerebrovascular accident. Neither death was re­
lated to flutamide (details in Table VIII).
L a b o r a t o r y  A b n o r m a l i t i e s
Of patients in various treatment arms, 1% to 3% 
had significant change (significant meaning from 
grade 0 to 2 at baseline to grade 3 to 4 during the 
study) in alkaline phosphatase, SGOT, and SGPT 
(0% in placebo). SGOT and SGPT increase oc­
curred most commonly in the 250 mg twice daily 
group (4% and 6%, respectively). No patient had 
any significant change in serum uric acid.
D i s c o n t i n u a t i o n  d u e  t o  A d v e r s e  E v e n t s
Sixteen percent of patients in the placebo group 
and 25% to 39% of patients in fhe flutamide groups 
discontinued the study due to adverse events. More
TABLE VII. Summary of total urinary symptom score at baseline and end of study
Placebo 
(n « 52)
125 mg BID
(n = 57)
250  mg OD 
(n -  55)
250  mg BID 
(n = 51)
250  mg TID 
{n » 59)
Baseline (median)
End study (median) 
Difference (A)
P value among groups
1 2
8
-2
NS
Key : BJD = twice daily; O P  = once daily; TID  = llwee finies diiify.
1 1
6
-3
NS
1 2
8
- 4
NS
12
9
- 3
NS
12
6
- 4
NS
TABLE VIII. Adverse events and concurrent illnesses occurring in a t least
5% of patients in any treatment group
Treatment Group (%)
Placebo 
(n = 74)
125 mg BID 
(n = 75)
250 mg OD 
(n = 69)
250  mg BID
(n = 74)
250  mg TID
(n = 75)
No. (%) of patients with any AE 45 (61) 60 (80) 54 (78) 66 (89) 63 (84)
Breast pain* 4(5) 38 (51) 36 (52) 31 (42) 32 (43)
Diarrhea* 10 (14) 22 (29) 21 (30) 25 (34) 22 (29)
Dizziness 2 (3) 1 (1) 2(3) 4 (5 ) 1 (1)
Dyspepsia 3(4) 1 (1) 1 (1) 1 (1) 7 (9)
Dysuria 1 (1) 1 (1) 2(3) 1 (1) 5 (7)
Gynecomastia* 2(3) 12 (16) 10 (14) 14(19) 11 (15)
Headache 3 (4) 1 (1) 2(3) 4 (5 ) 4(5)
Impotence 2(3) 2(3) 3 (4) 5(7) 6 (8)
Infection, viral 5(7) 3 (4) 3(4) 3 (4) 2 (3)
Influenza-like symptoms 2(3) 4(5) 3(4) 4 (5) 1 (1)
Libido, decreased 2 (3) 1 (1) 3(4) 3 (4) 5 (7)4
Nausea 2 (3) 2(3) 1 (1) 5 (7 ) 6(8)
Pain 2(3) 4(5) 2(3) 5 (7 ) 2(3)
Rhinitis 2(3) 4(5) 0(0) 0 (0 ) 1 (1)
Urinary tract infection 4(5) 3(4) 1 (1) 5 (7) 1 (1)
Ki-y: ac = adverse event; BID  = iw icc daily; OD  = on a ’ daily; TID = three times daily.
*P  <0.5 between Jlatam ide arm and placcbo. P = not s ign i/ia in f between various jh ita m id i dose groups.
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than 1 of 3 patients in each of the two highest dose 
groups discontinued due to two adverse events, 
and discontinuations began to occur mostly after
6 weeks of treatment. Most of the discontinuations 
were due to diarrhea (12% to 17%) or nipple and 
breast tenderness (4% to 8%). Of patients in vari­
ous treatment arms, 1% to 3% discontinued due to 
deranged liver enzymes (1% for placebo); and 1% 
to 4% due to impotence (1% for placebo).
COMMENT
The main findings of this study were: (1) flu- 
tamide reduced the prostate volume in a dose-re­
lated fashion (median reduction of 14% to 29% 
at 24 weeks; P <0.05) as early as 12 weeks; (2) 
dose-related increases in peak flow rate started at
4 weeks (3% for 250 mg three times daily; P value 
< 0.05), but the early positive effects did not 
maintain statistical significance due to an in­
creasing number of dropouts due to adverse 
events; (3) effect on PVR was observed only at 
the highest dose and at 24 weeks (median reduc­
tion, 23 mL; P <0.05); (4) despite volume reduc­
tion and early improvement in peak flow rate, 
there were no significant differences in urinary 
symptoms among the placebo and flutamide 
groups; (5) diarrhea was the most common se­
vere side effect, which occurred in a dose-related 
fashion (8% to 17%) and was responsible for al­
most half of the adverse event-related discontin­
uations. Other common adverse events were nip­
ple and breast tenderness and gynecomastia. 
Hepatic enzyme abnormalities led to discontinu­
ations infrequently and with the same incidence 
in the placebo and flutamide groups.
Even though the exact pathogenesis of BPH is 
poorly understood, it is clear that the presence of 
intact testicles and aging are the two most impor­
tant prerequisites for its development. It is ex­
tremely rare for BPH to occur in men who have un­
dergone castration either at puberty or before 40 
years of age. Postmortem studies on such patients 
(performed after 55 years of age) did not show his­
tologic evidence of BPH, whereas in age-matched 
controls it was present in more than 50% of men.6 7 
Many studies have shown the beneficial effects of 
androgen ablation using castration and luteinizing 
hormone-releasing hormone (LHRH) agonists in 
the treatment of BPH.8'10 Castration and LHRH ag­
onists, however, are associated with profound sex­
ual side effects, including impotence, loss of libido, 
and hot flushes. Hence this form of treatment was 
considered too drastic for a benign condition.
Flutamide, a 1a 1a-tri-fluoro-2-methyl-4'-nitro- 
m-propienotoluidide, is an orally administered 
nonsteroidal antiandrogen that is metabolized to 
a hydroxylated derivative (hydroxyflutamide).11-13 
It competes with both testosterone and DHT for
androgen receptor sites and binds to them. It has 
no antigonadotropic or progestational activity and 
thus does not suppress testosterone levels; there­
fore, sexual side effects are much less common.11' 
13 Canine and baboon studies have shown signif­
icant reduction in prostate volume and prostate 
epithelial cell height after flutamide therapy. Dur­
ing therapy, animals mated and sired several lit­
ters, suggesting lack of interference with sexual 
function and spermatogenesis. Based on the re­
sults of such animal studies, attempts were made 
to treat BPH with this drug. Caine and associates3 
in a placebo-controlled trial used flutamide (300 
mg/day) for 3 months to treat BPH. They did not 
find any significant reduction in prostate size; 
however, symptoms and uroflow improved. Lack 
of prostate size reduction was attributed to the 
short duration of the study.3
In another multicenter, randomized, double­
blind study involving 84 patients, Stone4 and 
Stone and Clejan 5 found a 41% median reduction 
in prostate size and a 46% increase in PFR at 24 
weeks with flutamide (750 mg/day). No similar 
reductions were seen in the placebo arm.4,5 How­
ever, significant improvement in symptoms was 
observed in both arms with no difference between 
the two groups. Eleven percent of patients had ei­
ther breast pain or diarrhea. No case of impotence 
was seen.
Even though total prostate volume was not mea­
sured before 12 weeks, based on the previous 
studies reduction in total prostate size was not ex­
pected before 90 days.14 However, it is interesting 
to note in the present study that improvement in 
uroflow started as early as 4 weeks and corre­
sponded to a simultaneous reduction in serum 
PSA. Significant prostate reduction was, however, 
noted at 12 months. Serum PSA and prostate vol­
ume reduction, however, continued dose-related 
reduction up to 24 weeks, at which time medica­
tion was stopped. Within 8 weeks following dis­
continuation of medication, both these parame­
ters started reverting to normal. This can be 
explained by the fact that any form of androgen 
ablation predominantly shrinks the transition 
zone. Such changes, however, do not translate 
into reduction in total prostate volume because of 
concomitant expansion of the peripheral zone, 
which is compressed earlier due to growth of aci­
nar tissue. Hence even though total prostate vol­
ume is not expected to reduce by 4 weeks, uroflow 
improvement occurred due to relief of prostate 
urethral compression by adenoma. This also cor­
related with the reduction in serum PSA. Later in 
the course of therapy when there was more pro­
nounced changes in the transition zone, total 
prostate volume was reduced. This correlation of 
transition zone, total prostate volume, and PFRs
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was shown in a study of 23 patients with BPH 
treated by finasteride in whom transition zone 
measurement was performed during transrectal 
ultrasound scanning.15
Lack of symptomatic improvement up to 24 
weeks of flutamide was a disappointing finding, 
and we do not have a definitive explanation for 
this. As seen in the other studies, uroflow and 
prostate volume changes did not correlate with 
symptom score changes. The term “prostatism” 
implies that the presence of the prostate gland is 
a necessary condition. However, these symptoms 
are also prevalent in an age-matched female pop­
ulation.16 Therefore, it is probably more rational 
to use the collective term “lower urinary tract 
symptoms” as proposed by Abrams.23 Other con­
ditions that may result in prostatism are detrusor 
instability and detrusor hypocontractility that may 
be present in 30% and 20%, respectively, of older 
men with prostatism. It is evident that these con­
ditions can be identified only by pressure flow 
urodynamic studies.2'1
In various clinical studies of BPH involving an­
drogen ablation, it was noted that there are no es­
tablished predictors of response. This may well 
be due to varying proportions of stromal and aci­
nar tissue in a particular adenoma. Antiandro­
gens are more likely to be effective in glands hav­
ing predominant acinar component,17 whereas 
alpha-blockers should work on stromal glands. 
This may be one of the reasons for lack of con­
sistency in response to medical therapy in man­
agement of BPH.18
Several new drug therapies (alpha-blockers and 
finasteride) have become available for the treat­
ment of BPH.18’19 Although, these medical agents 
have shown their efficacy in large clinical trials, it 
is not possible to predict good response in indi­
vidual patients. Hence selection of patients is still 
not based on scientific grounds. Urodynamic pa­
rameters may be helpful in predicting the out­
come of therapy and should therefore be included 
in at least a subgroup of patients in future clini­
cal trials evaluating newer medical agents.23
In this study, a lack of symptomatic improve­
ment was noted, although the prostate volume de­
creased significantly Further longer follow-up may 
be required before symptomatic improvement can 
be seen. Higher incidences of diarrhea, breast ten­
derness, and gynecomastia, however, were the 
main limiting factors in this study and until these 
problems are overcome, the role of flutamide in 
the management of BPH remains investigational.
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